Search...
Yifan Pharmaceutical Subsidiary Gets Regulatory Approval for Antifungal Drug
I'm PortAI, I can summarize articles.
(MT Newswires) -- Yifan Pharmaceutical (SHE:002019) subsidiary Hefei Yifan Biological Pharmaceutical obtained drug registration from China's medical products administrator for isavuconazole sulfate for injection. The broad-spectrum antifungal drug is used to treat infections such as aspergillosis and mucormycosis in adults, according to a filing with the Shanghai bourse. The validity is until September 2030. Shares of the pharmaceutical company were down 1% in recent trade.
Source: marketscreener The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments